The Formulation & Drug Delivery (FDD) Congress will welcome over 250 key leaders to discuss the state of the industry and look at the new strategies for optimizing biologic formulations such as antibodies, proteins and vaccines. In addition, updates will be discussed covering amorphous solid dispersions and combination products.
For more information on the FDD Congress agenda: click here
Sessions and case studies will be covering core topics of biologics, small molecule and inhaled therapies streams to highlight the composition on the next generation of medicinal therapeutics, as well as new feature streams.
Lonza will participate in formal and informal meetings with conference attendees discussing our most recent innovations in addressing key formulation challenges.
Join the Lonza team to learn how our enabling technologies and development services can help to rapidly advance your compounds.
On Tuesday March 17th, Dr. Michael Grass will chair a session on advances in drug delivery (room: Kensington 2) and give a presentation on in-vitro screening and enabling technology selection for poorly bioavailable compounds.
Formulation selection and in-vitro screening for oral bioavailability enhancement Michael Grass, Ph.D., Principal Scientist, Global R&D
Tuesday, 17 March 2020
Can't join the show? Check out our SimpliFiH Solutions™, an integrated drug substance and drug product service offer for the rapid advancement of poorly bioavailable molecules to the clinic. click here.
Use the form below to schedule a meeting with Lonza team during FDD US.